Anzeige
Mehr »
Login
Dienstag, 30.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Uran Boom: Die Bullen starten durch - spektakuläre Kursgewinne möglich
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
128 Leser
Artikel bewerten:
(0)

Global Pediatric Medicines Market to Grow at a CAGR of 4.9% by 2021: Key Vendors are GSK, Novartis, Pfizer & Sanofi

DUBLIN, August 15, 2017 /PRNewswire/ --

The "Global Pediatric Medicines Market 2017-2021" report has been added to Research and Markets' offering.

Research and Markets Logo

The global pediatric medicines market is expected to grow at a CAGR of 4.97% during the period 2017-2021. The pediatric medicines market is one of the emerging markets in the pharmaceutical sphere with huge unmet needs and requires support for better innovation and higher R&D investments.

Global Pediatric Medicines Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is inorganic growth strategies. Along with the huge unmet need of this market which provide ample organic growth opportunity, the vendors in the market are continuously looking for alliances and acquisitions which provide additional growth booster to the market. Such strategic alliances often result into expanded geographical footprint and impressive product line extension. Such inorganic growth strategies, lead to technological advances due to mutual collaboration in R&D and improved product portfolio, which acts as growth impetus.

According to the report, one of the major drivers for this market is the high pediatric population. The growing pediatric population is one of the key drivers of the global pediatric medicines market. The birth-rate is increasing rapidly in under developed and in developing nations. For instance, according to the Central Intelligence Agency, the highest birth-rate was registered in Niger, which is 4.4%. The birth-rate in densely populated countries such as India and China is also very high. For instance, the birth-rate in India is 1.9% and in China, it is 1.24%.

Key Vendors

  • GSK
  • Novartis
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • Abbott
  • Bristol-Myers Squibb
  • Cipla
  • Eisai Pharmaceuticals
  • Eli Lilly
  • F. Hoffman-La Roche
  • Glenmark
  • Others

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market overview

PART 06: Pipeline analysis

PART 07: Market segmentation by route of drug administration

PART 08: Market segmentation by disease type

PART 09: Geographical segmentation

PART 10: Drivers and challenges

PART 11: Market trends

PART 12: Vendor landscape

PART 13: Key vendor analysis

For more information about this report visit https://www.researchandmarkets.com/research/m3v62s/global_pediatric

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.